|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...3637383940414243444546...6566» |
- || GSK692342 / GSK, Bill & Melinda Gates Foundation
Trial completion date: Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease (clinicaltrials.gov) - Apr 23, 2014
P2, N=142, Completed, Sponsor: GlaxoSmithKline
Trial completion date: Dec 2014 --> Apr 2014
- ||| GSK692342 / GSK, Bill & Melinda Gates Foundation
Enrollment change: Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease (clinicaltrials.gov) - Apr 23, 2014
P2, N=142, Completed, Sponsor: GlaxoSmithKline
Trial completion date: Dec 2014 --> Apr 2014 N=240 --> 142
- |||| GSK692342 / GSK, Bill & Melinda Gates Foundation
Trial completion: Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease (clinicaltrials.gov) - Apr 23, 2014
P2, N=142, Completed, Sponsor: GlaxoSmithKline
N=240 --> 142 Active, not recruiting --> Completed
- ||||| Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK
Enrollment change: Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults (clinicaltrials.gov) - Apr 23, 2014
P3, N=165, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed N=500 --> 165
- ||||||| Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK
Trial completion: Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults (clinicaltrials.gov) - Apr 23, 2014
P3, N=165, Completed, Sponsor: GlaxoSmithKline
N=500 --> 165 Active, not recruiting --> Completed
- ||||| Nimenrix (MenACWY-TT) / Pfizer
Trial initiation date: Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination (clinicaltrials.gov) - Apr 23, 2014
P3, N=260, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Initiation date: May 2013 --> Apr 2013
- ||||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P4 trial: Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults. (clinicaltrials.gov) - Apr 23, 2014
P4, N=882, Not yet recruiting, Sponsor: Pfizer
- ||||| Green Cross TD Vaccine (GC1107) / Green Cross
Enrollment change: To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children (clinicaltrials.gov) - Apr 21, 2014
P2/3, N=311, Completed, Sponsor: Green Cross Corporation
Initiation date: May 2013 --> Apr 2013 N=171 --> 311
- New P2 trial: FASTFOOD: HRZE Fasted/Fed in Newly Diagnosed TB (clinicaltrials.gov) - Apr 21, 2014
P2, N=20, Recruiting, Sponsor: University Medical Centre Groningen
- Enrollment open: Implementation of a Sexual Health Intervention for Young Men Who Have Sex With Men (MSM) in Two Vietnamese Cities (clinicaltrials.gov) - Apr 21, 2014
P=N/A, N=1500, Recruiting, Sponsor: National Development and Research Institutes, Inc.
N=171 --> 311 Not yet recruiting --> Recruiting
- Enrollment open: FASTFOOD: HRZE Fasted/Fed in Newly Diagnosed TB (clinicaltrials.gov) - Apr 21, 2014
P2, N=20, Recruiting, Sponsor: University Medical Centre Groningen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||||| Green Cross TD Vaccine (GC1107) / Green Cross
Trial completion: To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children (clinicaltrials.gov) - Apr 21, 2014
P2/3, N=311, Completed, Sponsor: Green Cross Corporation
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment closed: Screening for Tuberculosis in HIV-infected Patients Eligible for Antiretroviral Treatment (clinicaltrials.gov) - Apr 20, 2014
P=N/A, N=812, Active, not recruiting, Sponsor: Lund University
Recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion, IO biomarker: Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia (clinicaltrials.gov) - Apr 20, 2014
P=N/A, N=1200, Completed, Sponsor: Lund University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| New P3 trial: Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents (clinicaltrials.gov) - Apr 17, 2014
P3, N=430, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- ||| AMG 108 / AstraZeneca
Enrollment change: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Apr 17, 2014
P2a, N=100, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed N=150 --> 100
- mupirocin / Generic mfg.
Enrollment open: Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants (clinicaltrials.gov) - Apr 16, 2014
P2, N=126, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=150 --> 100 Not yet recruiting --> Recruiting
- ||| Nimenrix (MenACWY-TT) / Pfizer
Enrollment closed: Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers (clinicaltrials.gov) - Apr 16, 2014
P2, N=202, Active, not recruiting, Sponsor: Novartis Vaccines
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: Study of AERAS-402 in Healthy Infants (clinicaltrials.gov) - Apr 16, 2014
P2, N=487, Completed, Sponsor: Aeras
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | mupirocin / Generic mfg.
Trial completion: Preventing Staphylococcal (Staph) Infection (clinicaltrials.gov) - Apr 15, 2014
P4, N=146, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| ceftriaxone / Generic mfg., ceftaroline fosamil / Generic mfg.
Enrollment closed: Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP) (clinicaltrials.gov) - Apr 15, 2014
P2/3, N=160, Active, not recruiting, Sponsor: Cerexa, Inc.
Recruiting --> Completed Recruiting --> Active, not recruiting
- || Trial completion: A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. (clinicaltrials.gov) - Apr 15, 2014
P3, N=13, Completed, Sponsor: Novartis Vaccines
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| GEN-004 / Genocea
New P2 trial: Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae (clinicaltrials.gov) - Apr 15, 2014
P2, N=90, Not yet recruiting, Sponsor: Genocea Biosciences, Inc.
- ||||| ceftriaxone / Generic mfg., ceftaroline fosamil / Generic mfg.
Enrollment change: A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia (clinicaltrials.gov) - Apr 14, 2014
P3, N=1225, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed N=771 --> 1225
- Biopsy: Labial Biopsy in Patients With Tuberculosis Disease (clinicaltrials.gov) - Apr 14, 2014
P=N/A, N=65, Completed, Sponsor: Hopital Lariboisière
- | vancomycin / Generic mfg., ceftriaxone / Generic mfg., ceftaroline fosamil / Generic mfg.
Trial completion: Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus (clinicaltrials.gov) - Apr 14, 2014
P4, N=49, Completed, Sponsor: Cerexa, Inc.
N=771 --> 1225 Active, not recruiting --> Completed
- ||||||| ceftriaxone / Generic mfg., ceftaroline fosamil / Generic mfg.
Trial completion: A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia (clinicaltrials.gov) - Apr 14, 2014
P3, N=1225, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Trial primary completion date: Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine (clinicaltrials.gov) - Apr 14, 2014
P3, N=433, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Trial primary completion date: Jul 2013 --> Apr 2013
- ||| Trial completion date: Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine (clinicaltrials.gov) - Apr 14, 2014
P3, N=433, Completed, Sponsor: Novartis Vaccines
Trial primary completion date: Jul 2013 --> Apr 2013 Trial completion date: Jul 2013 --> Apr 2013
- ||||||| Trial completion: Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine (clinicaltrials.gov) - Apr 14, 2014
P3, N=433, Completed, Sponsor: Novartis Vaccines
Trial completion date: Jul 2013 --> Apr 2013 Recruiting --> Completed
- | YHB1411-2 / Yuhan Corp
Trial completion: Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male Volunteers (clinicaltrials.gov) - Apr 13, 2014
P1, N=49, Completed, Sponsor: Yuhan Corporation
Recruiting --> Completed Active, not recruiting --> Completed
- |||| PF-06290510 / Pfizer
Trial completion: Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years (clinicaltrials.gov) - Apr 10, 2014
P1/2, N=284, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Privigen (human immune globulin intravenous 10%) / CSL Behring
New P2 trial: INSTINCT: Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial (clinicaltrials.gov) - Apr 9, 2014
P2, N=100, Recruiting, Sponsor: Anders Perner
- | New P2 trial: Efficacy of iOWH032 in Dehydrating Cholera (clinicaltrials.gov) - Apr 9, 2014
P2, N=326, Not yet recruiting, Sponsor: PATH
- cefixime / Generic mfg.
Enrollment open: The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study (clinicaltrials.gov) - Apr 9, 2014
P1, N=30, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ciprofloxacin IV / Generic mfg.
Enrollment closed: Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers (clinicaltrials.gov) - Apr 9, 2014
P1, N=40, Active, not recruiting, Sponsor: Elusys Therapeutics
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion: Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers (clinicaltrials.gov) - Apr 9, 2014
P1, N=280, Completed, Sponsor: Elusys Therapeutics
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- AERAS-404 / Sanofi
New P1 trial: A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404) (clinicaltrials.gov) - Apr 8, 2014
P1, N=40, Completed, Sponsor: Aeras
- || Enrollment closed: Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures (clinicaltrials.gov) - Apr 7, 2014
P=N/A, N=600, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Trial completion: Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years. (clinicaltrials.gov) - Apr 7, 2014
P3, N=264, Completed, Sponsor: Novartis
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Bexsero (meningococcal group B vaccine) / GSK
New P3 trial: Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants (clinicaltrials.gov) - Apr 6, 2014
P3, N=750, Not yet recruiting, Sponsor: Novartis
- Clinical: TANDEM: Pulmonary Tuberculosis Patients With Diabetes Mellitus (clinicaltrials.gov) - Apr 3, 2014
P=N/A, N=350, Not yet recruiting, Sponsor: Universitas Padjadjaran
- Clinical: NIDIAGDigest: Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders (clinicaltrials.gov) - Apr 3, 2014
P=N/A, N=4000, Not yet recruiting, Sponsor: Swiss Tropical & Public Health Institute
- ||| Enrollment open: Safety and Immunogenicity of Nyaditum Resae® Probiotic to Protect From Tuberculosis (clinicaltrials.gov) - Apr 2, 2014
P=N/A, N=60, Recruiting, Sponsor: Manresana de Micobacteriologia, SL
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Trial completion: N. Meningitidis Carriage Study (clinicaltrials.gov) - Apr 2, 2014
P=N/A, N=1000, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Enrollment change: A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults (clinicaltrials.gov) - Apr 1, 2014
P3, N=18, Active, not recruiting, Sponsor: Novartis Vaccines
Recruiting --> Completed N=130 --> 18
- | Enrollment closed: A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults (clinicaltrials.gov) - Apr 1, 2014
P3, N=18, Active, not recruiting, Sponsor: Novartis Vaccines
N=130 --> 18 Recruiting --> Active, not recruiting
- Enrollment change: Hyperglycemia in Surgical Infections (clinicaltrials.gov) - Mar 31, 2014
P=N/A, N=17, Completed, Sponsor: The University of Texas Health Science Center, Houston
Recruiting --> Active, not recruiting N=100 --> 17
- ||| Trial completion, Pneumococcal vaccines: Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants (clinicaltrials.gov) - Mar 31, 2014
P1, N=280, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
N=100 --> 17 Active, not recruiting --> Completed
- ||| Enrollment open: Detection of Chlamydia (CT) and Gonorrhea (NG) (clinicaltrials.gov) - Mar 26, 2014
P=N/A, N=6600, Recruiting, Sponsor: Meridian Bioscience, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting